Completed PHASE2 INTERVENTIONAL NCT00446186

MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)

Mk0476 Phase II Dose Finding Study -Allergic Rhinitis-

Sponsor: Organon and Co

Interventions Comparator: placebo / Duration of Treatment: 2 Weeks MK0476, montelukast sodium / Duration of Treatment: 2 Weeks

Updated 6 times since 2017 Last updated: Aug 12, 2024 Started: Feb 29, 2004 Primary completion: Mar 31, 2004 Completion: Mar 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00446186, this PHASE2 trial focuses on Rhinitis Allergic and remains completed. Sponsored by Organon and Co, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Mar 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organon and Co

Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.